Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;42(8):1909.
doi: 10.1111/liv.15336. Epub 2022 Jun 16.

Alcohol-related liver disease treatment and EBM

Alain Braillon  1 , Florian Naudet  2
Affiliations
Free article
Comment

Alcohol-related liver disease treatment and EBM

Alain Braillon et al. Liver Int. 2022 Aug.
Free article
No abstract available

PubMed Disclaimer

Comment in

  • Reply to "Alcohol-related liver disease treatment and EBM".
    Louvet A, Rolland B; panel of experts of the recommendations “Management alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines.”. Louvet A, et al. Liver Int. 2022 Oct;42(10):2346. doi: 10.1111/liv.15342. Epub 2022 Jun 26. Liver Int. 2022. PMID: 35727915 No abstract available.

Comment on

References

REFERENCES

    1. Louvet A, Trabut JB, Moreno C, et al. Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver Int. 2022;42(6):1330-1343. doi:10.1111/liv.15221
    1. Braillon A, Naudet F, Cristea IA, Lexchin J. Baclofen and alcohol use disorders: breakthrough or great white elephant? Alcohol Alcohol. 2020;55(1):49-50.
    1. Naudet F, Braillon A, Cristea IA, Lexchin J. Restoring the Bacloville trial: efficacy and harms. Addiction. 2020;115(11):2184-2186.
    1. Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018;27(11):1239-1248.
    1. Paré A. Workes (translated out of Latine by Johnson T). Th. Cotes and R. Young, London, 1634 (First English Edition). p. 1119. Available at https://wellcomecollection.org/works/hamvcbsv (p 1061/1143) accessed 30 April 2022.